Tumor Suppressor Genes Frequently Altered in Squamous Cell Carcinoma
Tumor suppressor genes, including TP53, TERT, KMT2D, NOTCH1, NOTCH2, and FAT1, were often altered...
Dissemination (Meeting Coverage)
Treatment for Sézary Syndrome Increases
The use of systemic and skin-directed therapies increased among patients with Sézary syndrome...
High Mortality Risk in Patients With Leukemia Hospitalized With CDI
Among patients with leukemia admitted to the hospital with Clostridioides difficile infection...
Various Racial Disparities in Patients With TP53m Acute Myeloid Leukemia
Black/Hispanic patients with TP53 mutation (m) acute myeloid leukemia (AML) had worse overall...
Various Racial Disparities in Patients With TP53m Acute Myeloid Leukemia
Black/Hispanic patients with TP53 mutation (m) acute myeloid leukemia (AML) had worse overall survival (OS) compared with White patients, according to study results presented by Talha Badar, MBBS, MD, at the 2022 American...
Once-Daily Radiotherapy Preferred by Patients With Limited Stage Small Cell Lung Cancer
High-dose, once-daily thoracic radiotherapy (TRT) and standard twice daily TRT were well tolerated...
Most Patients With Multiple Sclerosis Experience Spasticity Daily
Most patients with MS experience spasticity daily, with varying degrees of severity and duration,...
Multiple Sclerosis-Related Cognitive Impairment Perceptions Differ Between Patients & Physicians
Factors affecting self-reported cognitive impairment (CI) among patients with multiple sclerosis...
Quadruple Therapy Phase II Data for EGFR-mutated NSCLC
Atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) is a promising regimen for...
Determining Whether Adding RP1 to Cemiplimab Helps CSCC Patients
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Acalabrutinib Still Outperforming in R/R CLL: Three-years Follow-up of ASCEND
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
OS benefit seen in 5-year data on ELEVATE-TN trial in CLL
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
